Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist for the Treatment of PD-1 Refractory Melanoma & Dedifferentiated Liposarcoma - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist for the Treatment of PD-1 Refractory Melanoma & Dedifferentiated Liposarcoma

2:00 pm - Wednesday 14th October 2026

Introducing CAN1012 small molecule drug conjugate with TLR7 agonist immunomodulatory payload
Laying out rationale for liposarcoma indication selection and CAN1012 early clinical data leading to Orphan Drug Designation
Understanding the importance of indication selection in underserved cancer indications to maximize ADC first line potential and patient impact

Speakers:

Giorgio Massimini

Giorgio Massimini

CMO

CanWell Pharma Inc